

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

ALNYLAM PHARMACEUTICALS, INC.,

Plaintiff,

v.

C.A. No. 22-cv-335-CFC

MODERNA, INC., MODERNATX, INC.,
and MODERNA US, INC.,

Defendants.

DEFENDANTS' RULE 7.1 CORPORATE DISCLOSURE STATEMENT

Pursuant to Rule 7.1(a) of the Federal Rules of Civil Procedure, Defendants Moderna, Inc., ModernaTX, Inc., and Moderna US, Inc., by and through their attorneys, hereby make the following disclosures:

Defendant ModernaTX, Inc. is a wholly-owned subsidiary of Defendant Moderna, Inc. Defendant Moderna US, Inc. is a wholly-owned subsidiary of Defendant Moderna, Inc. Defendant Moderna, Inc. is a publicly traded company that has no parent corporation, and no publicly held corporation owns 10% or more of its stock.

Dated: May 23, 2022

Respectfully submitted,

OF COUNSEL:

FARNAN LLP

GIBSON, DUNN & CRUTCHER LLP

/s/ Brian E. Farnan

Jane M. Love, Ph.D.
Robert W. Trenchard
Emil N. Nachman
200 Park Avenue
New York, New York 10166
(212) 351-4000
JLove@gibsondunn.com
RTrenchard@gibsondunn.com
ENachman@gibsondunn.com

Brian E. Farnan (Bar No. 4089)
Michael J. Farnan (Bar No. 5165)
919 N. Market Street, 12th Floor
Wilmington, Delaware 19801
(302) 777-0300
(302) 777-0301
bfarnan@farnanlaw.com
mfarnan@farnanlaw.com

Anne Y. Brody
333 South Grand Avenue
Los Angeles, CA 90071
(213) 229-7000
ABrody@gibsondunn.com

*Attorneys for Moderna, Inc.,
ModernaTX, Inc., and Moderna US, Inc.*